ADMA Biologics
ADMA
13.17
-0.17
-1.27%
ADMA Biologics
US · ADMA
#2705 by market cap
Listed 1970
13.17
-0.17
-1.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.3 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 89.89% -1.35pp
- Institutions
- 389 +13
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund62.35%
Hedge Fund17.92%
Public Company3.96%
Individual/Insider1.89%
Government Pension Fund1.46%
Family Office/Trust1.46%
Private Company1.38%
VC/PE Fund1.12%
Other8.37%
Top holders as of 2026-09-30
BlackRock
16.82% · 37.31M sh
State Street Global Advisors
6.16% · 13.68M sh
Vanguard Capital Management, LLC
4.27% · 9.47M sh
Rubric Capital Management LP
4.21% · 9.34M sh
Vanguard Portfolio Management, LLC
4.15% · 9.21M sh
Capital Research
3.94% · 8.75M sh
First Trust Advisors L.P.
3.52% · 7.80M sh
Geode Capital Management, LLC
2.67% · 5.92M sh
Caligan Partners, LP
2.58% · 5.73M sh
D. E. Shaw & Co., L.P.
2.38% · 5.27M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Adam Grossman | Chief Executive Officer | 1.31% |
| Jerrold Grossman | Co-Founder & Vice Chairman of the Board | 0.25% |
| Young Kwon | Independent Director | 0.11% |
| Lawrence Guiheen | Independent Director | 0.08% |
| Kaitlin Kestenberg | COO & Senior VP of Compliance | 0.07% |
| Steven Elms | Independent Chairperson | 0.04% |
| Alison Finger | Independent Director | 0.02% |
| Eduardo Salas | Independent Director | 0.00% |
| Brad Tade | Former Consultant | 0.00% |
| P. Terence Kohler | Chief Financial Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-04 | Adam Grossman | Chief Executive Officer | Open Market Disposition | -42,000 | $12.00 |
| 2026-11-04 | Adam Grossman | Chief Executive Officer | Derivative Exercise and Sale | -105,000 | $5.40–12.00 |
| 2026-07-23 | Kaitlin Kestenberg | COO & Senior VP of Compliance | Sale to Issuer | -3,177 | $8.37 |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Acquisition | +85,130 | -- |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Derivative Acquisition | +136,363 | $8.81 |
| 2026-05-26 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +6,400 | $7.91 |
| 2026-05-11 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-05-10 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-03-31 | Kaitlin Kestenberg | COO & Senior VP of Compliance | Sale to Issuer | -20,362 | $9.11 |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Derivative Exercise and Sale | -30,000 | -- |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Other Acquisition | +30,000 | -- |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Automatic Disposition | -6,000 | $15.16 |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Derivative Exercise and Sale | -15,000 | $5.40–15.16 |
| 2026-03-09 | Brad Tade | Former Consultant | Intent to Sell (Form 144) | -50,026 | $15.81 |
| 2026-03-08 | Kaitlin Kestenberg | COO & Senior VP of Compliance | Other Disposition | -91,266 | -- |
| 2026-03-08 | Kaitlin Kestenberg | COO & Senior VP of Compliance | Derivative Exercise and Sale | -10,096 | $1.55–15.63 |
| 2026-03-06 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -85,951 | $15.39 |
| 2026-03-06 | Kaitlin Kestenberg | COO & Senior VP of Compliance | Sale to Issuer | -14,294 | $15.39 |
| 2026-03-05 | Aisling Capital Management LP | -- | Open Market Acquisition | +14,000 | $15.39–15.67 |
| 2026-02-25 | P. Terence Kohler | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ADMA Biologics discussion 0 comments